- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00557284
Efficacy Study of Montelukast in Atopic Dermatitis Induced by Food Allergens
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Montelukast (Singulair) in Participants Ages 1 - 8 Years Diagnosed With Atopic Dermatitis Induced by Food Allergens
AD is a disease found in children; the focus of the study is the mechanisms associated in children with AD induced by food allergies.
This study will be a randomized, double-blind, placebo-controlled, parallel group trial conducted in participants diagnosed with atopic dermatitis and food allergies. The study duration for participants will be approximately 9 weeks. A total of 20 participants will be recruited for the entire study. Each arm will consist of 10 participants.The study will enroll 20 children, male or female, 1 - 8 years of age with atopic dermatitis (AD) associated with food allergens, previously documented by skin or RAST test, before enrollment. Atopic dermatitis and gastrointestinal (GI) symptoms will be scored and followed throughout the study.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Colorado
-
Centennial, Colorado, United States, 80112
- 1st Allergy & Clinical Research Centers
-
Thornton, Colorado, United States, 80229
- 1st Allergy & Clinical Research Centers
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Mild to moderate atopic dermatitis involving greater than or equal to 5% of body surface
- Total severity score of 2 or greater for any 3 of the 4 signs and symptoms calculated by study doctor (erythema, papulation, or lichenification)
- Positive skin or (radioallergosorbent) RAST tests by ImmunoCap to food or environmental allergens
- GI symptoms total score of 2 by caregiver on GSRS scale revised for pediatrics
Exclusion Criteria:
- Participants with intolerance or allergy to montelukast.
- History of anaphylaxis requiring hospitalization.
- No underlying renal or liver disease.
- Participants with a diagnosis of severe asthma.
- Participants diagnosed with primary immune deficiency.
- Participants using sublingual immunotherapy.
- Immunotherapy must be a maintenance dose for a minimum of 30 days.
- If on gastrointestinal medication, 30 day stable dose before visit 1 and maintained throughout the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: 2
|
Oral granules or chewable tablet, PO QD (given oral daily)
|
Experimental: 1
Montelukast
|
4 mg oral granules for ages 12 - 23 months; 4 mg chewable tablet for 2 - 5 years of age; or 5 mg chewable tablet for 6 - 8 years of of age
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Percentage of Body Involvement
Time Frame: Baseline and 9 weeks
|
Change in percentage of body involvement from baseline to study visit 4 (week 1 compared to week 9) for all subjects in each arm for AD as measured by study investigator
|
Baseline and 9 weeks
|
Mean Change in Investigator Global Assessment (IGA)
Time Frame: Baseline and 9 weeks
|
The mean change in IGA from baseline to study visit 4 (week 1 compared to week 9) for all subjects in each arm.
The IGA is a six-point measure of disease severity and is evaluated by the investigator based on the overall assessment of skin lesions: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe, 5= very severe.
|
Baseline and 9 weeks
|
Mean Change in PADC (Caregivers Perception of Disease Control)
Time Frame: Baseline and 9 weeks
|
Mean change in PADC from baseline to study visit 4 (week 1 compared to week 9) for all subjects in each arm.
Caregiver's evaluation of disease control over the previous 7 days and will consist of a four-point scale ranging from complete control (0) to uncontrolled disease (3)
|
Baseline and 9 weeks
|
Mean Change in Pruritus
Time Frame: Baseline and 9 weeks
|
Mean change in pruritus scores from baseline to study visit 4 (week 1 compared to week 9) for all subjects in each arm.
Pruritus assessments ("itch") will be recorded for the previous 24 hours using a 4 point-scale, ranging from none (0) to severe (3).
Scores are cumulative per week.
|
Baseline and 9 weeks
|
Mean Change in Weekly Use of Rescue Medication for AD Flare-up - Cetirizine and/or 10% Hydrocortisone Cream
Time Frame: Baseline and 9 weeks
|
Average of weekly use of cetirizine and/or 10% hydrocortisone cream will be compared for all subjects in each arm from week 1 to week 9. Flare-up is defined as a worsening of the disease that is unacceptable to the participants and leads to second line topical steroid use and/or liquid anti-histamine use.
Measurement is noted as 1 for daily use (does not correspond to multiple uses per day).
|
Baseline and 9 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change in Serum and Urinary Inflammatory Marker Levels
Time Frame: Baseline and 9 weeks
|
Mean change in levels from baseline to study visit 4 (week 1 compared to week 9)for interleukin 3 (IL3), tumor necrosis factor alpha (TNF alpha), nerve growth factor (NGF), and urinary leukotriene E4 (LTE4)
|
Baseline and 9 weeks
|
Mean Change in Serum IgE Levels
Time Frame: Baseline and 9 weeks
|
Mean change in serum levels of IgE from baseline to study visit 4 (week 1 compared to week 9) for all subjects in each arm.
|
Baseline and 9 weeks
|
Mean Change in (Gastrointestinal Symptom Rating Scale) GSRS
Time Frame: Baseline and 9 weeks
|
The mean change from baseline to study visit 4 (week 1 compared to week 9) in GRGS scores (GI symptoms will be recorded on *GSRS validated scale adjusted for pediatrics (*Gastrointestinal Symptoms in Patients with Irritable Bowel Syndrome and Peptic Ulcer Disease) for all subjects in each arm.This scale measures 7 different GI symptoms (1.
abdominal pain; 2. nausea and vomiting; 3. abdominal dissention; 4. decreased passage of stools; 5. increased passage of stools; 6. loose stools; 7. hard stools) with severity ranges from 0 - 3 for each point (0 being no complaint and 3 being most severe for a maximum total of 21).
|
Baseline and 9 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Isaac R Melamed, MD, 1st Allergy & Clinical Research Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Immune System Diseases
- Hypersensitivity, Immediate
- Genetic Diseases, Inborn
- Skin Diseases, Genetic
- Hypersensitivity
- Skin Diseases, Eczematous
- Dermatitis
- Eczema
- Dermatitis, Atopic
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Anti-Asthmatic Agents
- Respiratory System Agents
- Leukotriene Antagonists
- Hormone Antagonists
- Cytochrome P-450 CYP1A2 Inducers
- Cytochrome P-450 Enzyme Inducers
- Montelukast
Other Study ID Numbers
- 32032
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atopic Dermatitis
-
Catalysis SLCompletedAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related Conditions | Atopic Dermatitis \(AD\)Serbia
-
Jacob Pontoppidan ThyssenThe Novo Nordic FoundationRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis FlareDenmark
-
ShaperonNot yet recruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis of Scalp
-
University of California, San FranciscoSanofi; Regeneron PharmaceuticalsRecruitingEczema | Atopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related ConditionsUnited States
-
PfizerActive, not recruitingEczema | Atopic Dermatitis | Eczema, Atopic | Atopic Dermatitis, UnspecifiedUnited States, Canada, Czechia, Poland
-
AmgenCompletedDermatitis, Atopic DermatitisCanada, United States, Japan
-
SanofiCompletedAtopic Dermatitis | Dermatitis AtopicChina
-
SanofiCompletedDermatitis AtopicSaudi Arabia, Kuwait, United Arab Emirates
-
Hadassah Medical OrganizationUnknownATOPIC DERMATITIS
-
Regeneron PharmaceuticalsSanofiRecruitingModerate-to-Severe Atopic Dermatitis | Atopic EczemaUnited States
Clinical Trials on Montelukast
-
Indiana UniversityCompleted
-
Chinese University of Hong KongUniversity of Sydney; Chongqing Medical University; Hong Kong University of Science... and other collaboratorsNot yet recruitingAtherosclerosis, CoronaryHong Kong
-
GlaxoSmithKlineCompleted
-
Kecioren Education and Training HospitalCompletedAsthma | Acute AsthmaTurkey
-
Menarini International Operations Luxembourg SACompletedAsthma | Seasonal Allergic RhinoconjunctivitisPoland, Romania, Germany, Italy, Czechia, Latvia, Croatia, Slovakia
-
Organon and CoCompleted
-
Medical University of LodzUnknownSeasonal Allergic RhinitisPoland
-
GlaxoSmithKlineCompletedRespiratory Disorders | Asthma and RhinitisIndia
-
Qilu Pharmaceutical Co., Ltd.Completed
-
Kecioren Education and Training HospitalCompletedAcute Asthma | Acute Wheezy BronchitisTurkey